These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21980965)

  • 1. Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.
    Cousins D; Topping K; Lee V; Sweeney J; Lawton M
    Drug Metabol Drug Interact; 2011; 26(3):139-41. PubMed ID: 21980965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.
    Bickel M; Anadol E; Vogel M; Hofmann WP; von Hentig N; Kuetscher J; Kurowski M; Moench C; Lennemann T; Lutz T; Bechstein WO; Brodt HR; Rockstroh J
    J Antimicrob Chemother; 2010 May; 65(5):999-1004. PubMed ID: 20202988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.
    Barau C; Blouin P; Creput C; Taburet AM; Durrbach A; Furlan V
    Fundam Clin Pharmacol; 2009 Aug; 23(4):423-5. PubMed ID: 19709321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal transplantation in HIV-infected patients in Spain].
    Mazuecos A; Pascual J; Gómez E; Sola E; Cofán F; López F; Puig-Hooper CE; Baltar JM; González-Molina M; Oppenheimer F; Marcén R; Rivero M
    Nefrologia; 2006; 26(1):113-20. PubMed ID: 16649432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
    Wandeler G; Furrer H; Rauch A
    AIDS; 2011 Nov; 25(18):2306-8. PubMed ID: 22067200
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.
    Cocohoba J
    Expert Rev Anti Infect Ther; 2009 Dec; 7(10):1159-63. PubMed ID: 19968507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
    Di Biagio A; Rosso R; Siccardi M; D'Avolio A; Bonora S; Viscoli C
    J Antimicrob Chemother; 2009 Oct; 64(4):874-5. PubMed ID: 19643773
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.
    Mertz D; Battegay M; Marzolini C; Mayr M
    Am J Kidney Dis; 2009 Jul; 54(1):e1-4. PubMed ID: 19346040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study.
    van Maarseveen EM; Crommelin HA; Mudrikova T; van den Broek MP; van Zuilen AD
    Transplantation; 2013 Jan; 95(2):397-402. PubMed ID: 23250333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.